Lhuintre J P, Daoust M, Moore N D, Chretien P, Saligaut C, Tran G, Bosimare F, Hillemand B
Lancet. 1985 May 4;1(8436):1014-6. doi: 10.1016/s0140-6736(85)91615-0.
After they had been weaned off alcohol in hospital 85 severe alcoholics (above 200 g alcohol/day) were included in a double-blind study of calcium bis acetyl homotaurine (Ca AOTA, 25 mg/kg/day), a new gamma-aminobutyric acid agonist, versus placebo. Patients were treated as outpatients during the 3-month study. The only other treatment that patients received was meprobamate, 800 to 1200 mg/day, in the first month. The criterion for success was abstinence at 3 months (with normal gamma-glutamyl transpeptidase being one of the criteria). Of the 70 patients who completed the study, 33 received Ca AOTA and 37 placebo. 20 patients on Ca AOTA did not relapse, compared with 12 on placebo (p less than 0.02 by X2 test). Side-effects were noted by 7 patients on Ca AOTA and 2 on placebo. The results suggest that Ca AOTA may be useful in helping severe alcoholics who have been weaned off alcohol not to relapse.
85名重度酗酒者（每日饮酒量超过200克酒精）在医院戒酒之后，被纳入一项双盲研究，该研究对比了新型γ-氨基丁酸激动剂双乙酰高牛磺酸钙（Ca AOTA，25毫克/千克/天）与安慰剂的效果。在为期3个月的研究期间，患者作为门诊病人接受治疗。患者在第一个月接受的唯一其他治疗是眠尔通，每天800至1200毫克。成功的标准是在3个月时戒酒（γ-谷氨酰转肽酶正常是标准之一）。在完成研究的70名患者中，33名接受了Ca AOTA治疗，37名接受了安慰剂治疗。接受Ca AOTA治疗的20名患者未复发，而接受安慰剂治疗的为12名（经卡方检验，p小于0.02）。接受Ca AOTA治疗的7名患者和接受安慰剂治疗的2名患者出现了副作用。结果表明，Ca AOTA可能有助于帮助已戒酒的重度酗酒者避免复发。
